Sanofi Ventures Secures $625M to Strengthen Biotech Innovation

Sanofi has declared a new $625 million multi-year capital commitment to its venture arm, Sanofi Ventures, bringing its total managed assets to over $1.4 billion.

This is a considerable enlargement of the evergreen venture fund as it firmly invests in developing early-stage biotech and digital health innovations around the world.

Since inception in 2012, Sanofi Ventures has invested over $800 million into more than 70 companies in areas such as immunology, rare diseases, neurology, vaccines, and digital health. The fund invests in all stages of financing, from seed stage to crossover, and is active on companies’ boards and during IPOs.

Also Read: Unlocking India's Innovation Potential in Pharma

Paul Hudson, Sanofi’s CEO, said the new funding represents the company’s belief that some of the most significant medical discoveries begin in the early-stage companies. Jason P. Hafler, PhD, Managing Director of Sanofi Ventures, indicated that the fund’s “evergreen structure" has been validated with strong performance and three exits in 2024 with a total acquisition value of $3.25 billion.

This new commitment comes at a time when funding for early-stage biotech is shrinking, leaving Sanofi Ventures well-positioned to fill funding gaps for promising science. We intend to utilize this capital to accelerate our pipeline of next-generation therapies and continue using Sanofi's unique position as a catalyst for breakthrough science and healthcare innovation.